The biotech industry is becoming the most active group for later-stage pipeline work, and while Big Pharma sees its R&D share drop, emerging life science companies are better prepared to go it alone.
This is according to a new report by the IQVIA Institute for Human Data Science, “The Changing Landscape of Research and Development: Innovation, Drivers of Change, and Evolution of Clinical Trial Productivity.”
The IQVIA report (the company merged from pharma analytics firm IMS Health and CRO Quintiles) has put together an index that “reflects changes in trial complexity, success and duration” over a 10-year historical view of these metrics and “recasts the data with a future perspective that identifies critical productivity changes expected through 2023.”
Last year was a bumper year for FDA approvals, with 59 new therapies getting the thumbs-up under the leadership of the (now ex) FDA Commissioner Scott Gottlieb. But the report points out that large pharmas were the filing companies for fewer than half of these launches. Emerging biopharma companies, however, were the originator of 38 of the 59 meds (64%).
The report says that the “importance of large pharma in originating molecules is decreasing,” but they “remain important partners” for biotech. Still, they see the need for smaller biopharmas to team up with Big Pharma companies—and their large sales teams—as becoming less important.
“The dynamics of development, M&A and licensing activity seem to be shifting, and emerging companies are retaining control of their assets to a greater degree,” the report’s authors write.
Coupled with this is the fact that, according to the index, emerging biopharma companies (the report sees these as spending less than $200 million annually on R&D and less than $500 million in sales) account for 72% of all late-stage pipeline activity, up from 61% a decade ago.
Big Pharma still spends a large amount on R&D: The top 15 largest companies funneled more than $100 billion for the first time last year, but the data show large pharma companies (those with more than $10 billion in yearly drug sales) have seen their R&D share drop from 31% to just 20% in the past decade.
“This pipeline mix reflects smaller companies being most active in the fastest growing areas of oncology and orphan drugs, and their diminishing need for partnering or acquisition to develop and commercialize their innovative medicines,” the report found.
Good news abounds for life science companies, as investment in medical innovation also grew in 2018, “reflecting confidence in scientific development to propel new treatments to tackle unmet health needs across a broad range of diseases.”
Last year, more than 1,300 life science venture capital deals were closed with an aggregate value of more than $23 billion, up around $10 billion in deal value from five years earlier, according to the National Venture Capital Association.
Times from patent filing to product launch have also come down by half a year, in median terms, over the past five years, but it’s still a slow process overall—13.7 years on average, according to the data.
“Of the 2018 new drug launches, four new molecular entities launched in less than eight years, while another 12 drugs launched more than 20 years after their first patent filing, reflecting in some cases older mechanisms of action and the approval of drugs that had launched in countries outside the U.S.”
The report also highlighted the growing importance of artificial intelligence, real-world data, patient-reported outcomes and stronger biomarkers and diagnostics in both trials and post-marketing tests to really drive productivity and better shots on goal in drug development and beyond.
By Ben Adams
Source: Fierce Biotech
As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.
McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.
AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.